• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1992年至1997年加拿大蒙特利尔脆弱拟杆菌群临床分离株的抗菌药物耐药性趋势

Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada.

作者信息

Labbé A C, Bourgault A M, Vincelette J, Turgeon P L, Lamothe F

机构信息

Département de Microbiologie Médicale et Infectiologie, Centre Hospitalier de l'Université de Montréal, Montréal, Canada.

出版信息

Antimicrob Agents Chemother. 1999 Oct;43(10):2517-9. doi: 10.1128/AAC.43.10.2517.

DOI:10.1128/AAC.43.10.2517
PMID:10508035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC89511/
Abstract

The objective of the present study was to analyze the susceptibility profiles of 911 clinical strains of the Bacteroides fragilis group isolated from 1992 to 1997 in our institution in order to monitor susceptibility changes over time. Whereas the rates of resistance to metronidazole, imipenem, piperacillin-tazobactam, ticarcillin-clavulanic acid, penicillin, piperacillin, and cefoxitin remained essentially unchanged, there was a significant increase in the rates of resistance to clindamycin, which rose from 8.2% in 1992 to 19.7% in 1997 (P < 0.0004).

摘要

本研究的目的是分析1992年至1997年期间从我们机构分离出的911株脆弱拟杆菌属临床菌株的药敏谱,以监测随时间的药敏变化。虽然对甲硝唑、亚胺培南、哌拉西林-他唑巴坦、替卡西林-克拉维酸、青霉素、哌拉西林和头孢西丁的耐药率基本保持不变,但对克林霉素的耐药率显著增加,从1992年的8.2%升至1997年的19.7%(P<0.0004)。

相似文献

1
Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada.1992年至1997年加拿大蒙特利尔脆弱拟杆菌群临床分离株的抗菌药物耐药性趋势
Antimicrob Agents Chemother. 1999 Oct;43(10):2517-9. doi: 10.1128/AAC.43.10.2517.
2
Survey of Bacteroides fragilis group susceptibility patterns in Canada.加拿大脆弱拟杆菌群药敏模式调查。
Antimicrob Agents Chemother. 1992 Feb;36(2):343-7. doi: 10.1128/AAC.36.2.343.
3
Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.脆弱拟杆菌群中对头孢西丁耐药和敏感菌株对β-内酰胺-β-内酰胺酶抑制剂组合及克林霉素的交叉耐药性
Diagn Microbiol Infect Dis. 1993 Oct;17(3):251-6. doi: 10.1016/0732-8893(93)90107-i.
4
Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.脆弱拟杆菌群物种及其他厌氧菌对美罗培南、亚胺培南、哌拉西林、头孢西丁、氨苄西林/舒巴坦、克林霉素和甲硝唑的敏感性比较。
J Antimicrob Chemother. 1993 Mar;31(3):363-72. doi: 10.1093/jac/31.3.363.
5
Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.来自阿根廷布宜诺斯艾利斯的脆弱拟杆菌群分离株的药敏趋势。
Rev Argent Microbiol. 2007 Jul-Sep;39(3):156-60.
6
Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.1990年至1994年间脆弱拟杆菌群临床分离株抗菌药物耐药模式的趋势分析。
Clin Infect Dis. 1996 Dec;23 Suppl 1:S54-65. doi: 10.1093/clinids/23.supplement_1.s54.
7
In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.克林霉素、亚胺培南、甲硝唑和哌拉西林-他唑巴坦对脆弱拟杆菌敏感和耐药分离株的体外活性评价——通过杀菌动力学。
Antimicrob Agents Chemother. 2012 Jun;56(6):3413-6. doi: 10.1128/AAC.00099-12. Epub 2012 Mar 19.
8
Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.1997年至2004年韩国8年间脆弱拟杆菌群的耐药趋势
Korean J Lab Med. 2009 Aug;29(4):293-8. doi: 10.3343/kjlm.2009.29.4.293.
9
Susceptibility trends of Bacteroides fragilis group and characterisation of carbapenemase-producing strains by automated REP-PCR and MALDI TOF.脆弱拟杆菌群的药敏趋势及采用自动化 REP-PCR 和 MALDI-TOF 对产碳青霉烯酶菌株的特征分析。
Anaerobe. 2012 Feb;18(1):37-43. doi: 10.1016/j.anaerobe.2011.12.022. Epub 2012 Jan 11.
10
Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents.114株脆弱拟杆菌属菌株对亚胺培南及其他8种抗菌药物的敏感性
Pathology. 1988 Jul;20(3):260-3. doi: 10.3109/00313028809059504.

引用本文的文献

1
Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline.复杂腹腔内感染或复杂皮肤和皮肤结构感染的难处理患者中的抗生素优化:重点关注替加环素。
Ther Clin Risk Manag. 2010 Sep 7;6:419-30. doi: 10.2147/tcrm.s9117.
2
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.引起医院感染的临床重要厌氧菌和脆弱拟杆菌分离株的抗菌药物耐药性呈上升趋势:对碳青霉烯类药物出现耐药性。
Antimicrob Agents Chemother. 2008 Sep;52(9):3161-8. doi: 10.1128/AAC.00355-08. Epub 2008 Jul 14.
3
Bacteroides fragilis group: trends in resistance.脆弱拟杆菌群:耐药性趋势
Curr Microbiol. 2006 Feb;52(2):153-7. doi: 10.1007/s00284-005-0249-x. Epub 2006 Jan 31.
4
Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.加雷沙星(BMS-284756)及其他药物对厌氧临床分离株的活性。
Antimicrob Agents Chemother. 2003 Mar;47(3):910-6. doi: 10.1128/AAC.47.3.910-916.2003.
5
High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.台湾厌氧菌中头孢西丁和克林霉素耐药性的高发生率。
Antimicrob Agents Chemother. 2002 Sep;46(9):2908-13. doi: 10.1128/AAC.46.9.2908-2913.2002.
6
In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.替加环素(GAR-936)对西班牙近期分离的临床细菌的体外活性。
Antimicrob Agents Chemother. 2002 Mar;46(3):892-5. doi: 10.1128/AAC.46.3.892-895.2002.
7
In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains.MK-0826及其他16种抗菌药物对脆弱拟杆菌群菌株的体外活性
Antimicrob Agents Chemother. 2001 Aug;45(8):2372-4. doi: 10.1128/AAC.45.8.2372-2374.2001.
8
Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.脆弱拟杆菌群、普雷沃菌属、梭杆菌属、卟啉单胞菌属和消化链球菌属临床分离株体外抗菌药敏变化的多中心调查。
Antimicrob Agents Chemother. 2001 Apr;45(4):1238-43. doi: 10.1128/AAC.45.4.1238-1243.2001.

本文引用的文献

1
Trends in antimicrobial resistance of the Bacteroides fragilis group: a 20-year study at a medical center in Buenos Aires, Argentina.脆弱拟杆菌群的抗菌药物耐药性趋势:在阿根廷布宜诺斯艾利斯一家医疗中心进行的一项为期20年的研究。
Clin Infect Dis. 1997 Sep;25 Suppl 2:S268-9. doi: 10.1086/516192.
2
Clindamycin resistance in the Bacteroides fragilis group: association with hospital-acquired infections.脆弱拟杆菌群中的克林霉素耐药性:与医院获得性感染的关联
Clin Infect Dis. 1997 May;24(5):874-7. doi: 10.1093/clinids/24.5.874.
3
Antimicrobial resistance in anaerobes.厌氧菌中的抗菌药物耐药性。
Clin Infect Dis. 1997 Jan;24 Suppl 1:S110-20. doi: 10.1093/clinids/24.supplement_1.s110.
4
Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea.韩国厌氧菌对抗菌药物的新出现耐药性。
Clin Infect Dis. 1996 Dec;23 Suppl 1:S73-7. doi: 10.1093/clinids/23.supplement_1.s73.
5
Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.1990年至1994年间脆弱拟杆菌群临床分离株抗菌药物耐药模式的趋势分析。
Clin Infect Dis. 1996 Dec;23 Suppl 1:S54-65. doi: 10.1093/clinids/23.supplement_1.s54.
6
Present studies of therapy for anaerobic infections.目前关于厌氧菌感染治疗的研究。
Clin Infect Dis. 1996 Dec;23 Suppl 1:S9-14. doi: 10.1093/clinids/23.supplement_1.s9.
7
Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers.在三个医学中心对脆弱拟杆菌群的物种对五种抗菌药物的敏感性进行的纵向研究。
Antimicrob Agents Chemother. 1994 Oct;38(10):2276-9. doi: 10.1128/AAC.38.10.2276.
8
Survey of anaerobic susceptibility patterns in Canada.加拿大厌氧菌药敏模式调查。
Antimicrob Agents Chemother. 1986 Nov;30(5):798-801. doi: 10.1128/AAC.30.5.798.
9
Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain.西班牙脆弱拟杆菌群菌株的抗菌药物敏感性演变
Rev Infect Dis. 1990 Jan-Feb;12 Suppl 2:S142-51. doi: 10.1093/clinids/12.supplement_2.s142.
10
Survey of Bacteroides fragilis group susceptibility patterns in Canada.加拿大脆弱拟杆菌群药敏模式调查。
Antimicrob Agents Chemother. 1992 Feb;36(2):343-7. doi: 10.1128/AAC.36.2.343.